治疗非小细胞肺癌新药阿法替尼的研究进展  

Progress in research of afatinib for non-small cell lung cancer

作　　者：王彩霞[1,2] 谢俊霞[3] 米毅[1,2] 赵倩[1,2] 

机构地区：[1]石药集团中奇制药技术(石家庄)有限公司,河北石家庄050035 [2]新型药物制剂与辅料国家重点实验室,河北石家庄050035 [3]河北化工医药职业技术学院,河北石家庄050026

出　　处：《沈阳药科大学学报》2015年第3期245-248,共4页Journal of Shenyang Pharmaceutical University

基　　金：重大新药创制-石家庄高端医药产业园区创新药物孵化基地课题任务(2011ZX09401-306)

摘　　要：目的评价治疗非小细胞肺癌新药阿法替尼的作用机制、药效学、安全药理学、毒理学、临床药动学和临床疗效。方法查阅相关文献15篇。结果与结论阿法替尼是表皮生长因子受体(epidermal grow th factor receptor,EGFR)和人表皮生长因子受体2(human epidermalgrow th factor receptor-2,HER2)酪氨酸激酶的强效、不可逆的双重抑制剂,作为伴有EGFR突变的肺癌患者一线治疗药物,疗效优于标准化疗方案,对吉非替尼和厄洛替尼耐药的非小细胞肺癌患者具有较好的临床获益。Objective To investigate afatinib＇ s mechanism, pharmacology, pharmacokinetics, safety pharmacology, toxicology, clinical pharmacology and clinical pharmacodynamics. Methods Related papers and reports were reviewed. Results and Conclusion Afatinib, an irreversible EGFR/HER2 inhibitor is used for the first-line treatment of patients with NSCLC whose tumors have EGFR mutations. Afatinib is more effective than standard chemotherapy and offers clinical benefit to the erlotinib and gefitinib-resistant patients.

关 键 词：阿法替尼 非小细胞肺癌 靶向治疗 

分 类 号：R96[医药卫生—药理学]